A Phase 1/2 interventional study of mRNA-3745 in Glycogen Storage Disease, sponsored by ModernaTX, Inc.. Active, not recruiting at 16 sites in 6 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Glycogen Storage Disease with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Glycogen Storage Disease · United States.
Among the 16 studies in Glycogen Storage Disease with a site in United States, this one is the only one that started in 2022, is one of 5 in phase 1/2, and was the 12th registered.
36 studies on the registry are indexed under Glycogen Storage Disease; 13 are open to participants now.
Browse Glycogen Storage Disease studies →5 of the 16 studies in Glycogen Storage Disease with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
AskBio Inc · Sites in United States
Ages 18–65
Shionogi · Sites in United States, Belgium, Denmark and 6 more countries
Ages 18+
Duke University · Sites in United States
Ages 0–90
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Glycogen Storage Disease studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6
First in 1992; this study’s year is marked. 1 started in 2022.
This study's enrollment of 15 is close to the median of 16 across 18 interventional studies indexed under Glycogen Storage Disease.
Median enrollment 14 across the 8 interventional studies, 45 across the 8 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Moderna, Inc. has 1 study filed under Glycogen Storage Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Glycogen Storage Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05095727ModernaTX, Inc.A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | 2026-11-30 |
| NCT07123155ShionogiStudy of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | 2027-08-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Glycogen Storage Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
The study includes a single ascending dose (SAD) stage and a multiple ascending dose (MAD) stage. Participants enrolled in the MAD stage have the option to continue treatment in an open-label extension (OLE) period that will assess long-term safety and clinical activity of mRNA-3745.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Participants will receive a single intravenous (IV) dose of mRNA-3745 on Day 1 in an inpatient setting. Participants that are/have been enrolled in the study and receive an administration of mRNA-3745 may also enroll in one of the MAD cohorts. The first MAD dose must occur at least 21 days after the SAD dose.
Drug: mRNA-3745
Participants will receive multiple IV doses of mRNA-3745 in an inpatient setting. Participants will have the option to continue treatment in the OLE.
Drug: mRNA-3745
Sterile frozen liquid dispersion for injection
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation
Time frame: Day 1 up to approximately 3.5 years
Number of Participants Not Experiencing Hypoglycemia During Fasting Challenges
Hypoglycemia is defined as blood glucose \<60 milligrams (mg)/deciliter (dL) (3.3 millimoles \[mmol\]/liter \[L\]) and/or symptoms of hypoglycemia.
Time frame: Baseline through up to Week 32
Change From Baseline of Area Under the Effect Curve (AUEC) of Blood Glucose and Lactate During Fasting Challenges
Time frame: Baseline through up to Week 32
Change From Baseline in Time to Hypoglycemia During Fasting Challenges
Time frame: Baseline through up to Week 32
Change From Baseline in Maximum Effect (Emax) During Fasting Challenges
Time frame: Baseline through up to Week 32
SAD only: Maximum Observed Concentration (Cmax) of Messenger Ribonucleic Acid (mRNA) and Lipid Nanoparticle (LNP)
Time frame: Pre-infusion, during infusion, at the end of infusion (EOI) and post-infusion on Day 1 up to Week 52
SAD only: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of mRNA and LNP
Time frame: Pre-infusion, during infusion, at EOI and post-infusion on Day 1 up to Week 52
Change From Baseline in Metabolic Biomarkers of GSD1a
Time frame: Baseline through up to approximately 6.5 years
MAD only: Maximum Observed Concentration at Steady State (Cmax,ss) of mRNA and LNP
Time frame: Pre-infusion, during infusion, at the EOI and post-infusion on Day 1 up to Week 52
Started Jun 2022 (actual). Primary completion is estimated for Nov 2026, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.